NCT06581575View on ClinicalTrials.gov

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

467

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Herpes Zoster (HZ)Infectious DiseasesShingles
Interventions
BIOLOGICAL

JCXH-105

IM injection

BIOLOGICAL

Shingrix

IM injection

Trial Locations (8)

29407

Delricht Research, Charleston

60652

DM Clinical Research - Chicago, Chicago

68114

Quality Clinical Research, Omaha

75078

Delricht Research, Prosper

77478

DM Clinical Research - Sugarland, Sugar Land

85704

Noble Clinical Research, Tucson

90805

Long Beach Research Institute, Long Beach

07306

DM Clinical Research - New Jersey, Jersey City

Sponsors
All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Immorna Biotherapeutics, Inc.

INDUSTRY

NCT06581575 - A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine | Biotech Hunter | Biotech Hunter